Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 4,058 shares of common stock at $485.49 per share on March 4, 2025, under a pre-arranged trading plan.

Summary

• On March 4, 2025, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, sold 4,058 shares of the company's common stock.
• The sale was executed at a price of $485.49 per share.
• The transaction was conducted under a company-approved trading plan pursuant to Rule 10b5-1, which was established on November 22, 2024.
• Following the transaction, Tatsis directly owns 54,481 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning and diversification. The use of 10b5-1 trading plans allows insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder perception, but is unlikely to be significant given the pre-planned nature of the sale.

Key Dates